Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance. Pfizer showed modest growth with a 5.4% revenue increase in Q1 2026, focusing on oncology and obesity treatments while COVID-related products declined. For 2027, Lilly is favored for its high growth potential with new drug filings and expanding international demand, while Pfizer offers a defensive value play with dividends and pipeline reinvestment. Investors seeking growth are advised to consider Lilly despite its premium valuation, whereas Pfizer suits those prioritizing yield and stability.
As of Sep 23, 2026 22:41 WIB, Eli Lilly trades at USD 1,156.91 with a 1-day decline of 1.16% on Pluang. Pfizer is priced at USD 28.11 and gained 0.66% in the same period. Investors on Pluang hold Pfizer longer, with a typical hold time of 156 days, compared to 93 days for Lilly, reflecting differing investment approaches in the pharmaceutical sector.
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Ken Langone, co-founder of Home Depot, stated that Eli Lilly stock could reach $2,000 within the next 3 to 4 years, challenging the long-term success of his Home Depot investment. Eli Lilly has shown strong growth, up over 54% in the past year despit...
Eli Lilly reported a strong quarter beating revenue and earnings estimates, driven by its dominant GLP-1 obesity and diabetes drugs Mounjaro and Zepbound. Despite this, the stock fell 7.2% over the past month due to pricing pressures and competition....
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
